公开(公告)号：US10106556B2

公开(公告)日：2018-10-23

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Tatsuki Koike ,  Jumpei Aida ,  Makoto Fushimi ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Masako Miyazaki ,  Hidekazu Tokuhara ,  Yasushi Hattori ,  Makoto Kamata

IPC: C07D498/04 ,  C07D413/14 ,  C07D401/06 ,  C07D413/06 ,  C07D417/14 ,  C07D471/04 ,  C07D401/10 ,  C07D413/10 ,  C12N9/99 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11834409B2

公开(公告)日：2023-12-05

申请号：US18087233

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Makoto Kamata ,  Yuya Oguro ,  Masataka Murakami ,  Minoru Nakamura ,  Fumie Yamaguchi ,  Takafumi Yukawa

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US09643957B2

公开(公告)日：2017-05-09

申请号：US14650429

申请日：2013-12-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Yuichi Kajita ,  Masato Yoshikawa ,  Shuhei Ikeda ,  Hiromi Fukuda

IPC: C07D403/12 ,  C07D471/08 ,  C07D491/08 ,  C07D213/12 ,  C07D498/08 ,  C07D405/12 ,  C07D401/14 ,  C07D417/14 ,  C07D451/04 ,  C07D487/10 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D401/12 ,  C07D239/42 ,  C07D413/04 ,  C07D417/04 ,  C07D451/02 ,  C07D487/18 ,  C07D491/18 ,  C07D403/04 ,  C07D403/14 ,  C07D471/10 ,  A61K9/20 ,  A61K9/48 ,  C07D213/72 ,  C07D487/08 ,  C12N9/99

CPC classification number: C07D498/08 ,  A61K9/2018 ,  A61K9/4858 ,  C07D213/12 ,  C07D213/72 ,  C07D213/74 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D451/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C12N9/99

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US09598398B2

公开(公告)日：2017-03-21

申请号：US14781963

申请日：2014-04-03

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Haruhi Ando ,  William John Farnaby ,  Shuhei Ikeda ,  Yuichi Kajita ,  Toshiya Nishi

IPC: C07D401/14 ,  C07D403/14 ,  A61K31/497 ,  A61K31/4545 ,  A61K31/444 ,  C07D401/10 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D401/12 ,  C07D239/26 ,  C07D417/14 ,  C07D213/34 ,  C07D213/56 ,  C07D213/42

CPC classification number: C07D401/10 ,  C07D213/34 ,  C07D213/42 ,  C07D213/56 ,  C07D239/26 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.

公开(公告)号：US11274101B2

公开(公告)日：2022-03-15

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto Kamata ,  Hideyuki Sugiyama ,  Minoru Nakamura ,  Masataka Murakami ,  Shuhei Ikeda ,  Tomohiro Okawa ,  Hidekazu Tokuhara

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US09624170B2

公开(公告)日：2017-04-18

申请号：US15108000

申请日：2014-12-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Makoto Fushimi ,  Jumpei Aida ,  Shuhei Ikeda ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Hidekazu Tokuhara

IPC: C07D207/273 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D471/04 ,  C07D405/12 ,  C07D417/14 ,  C07D417/12 ,  C07D413/12 ,  C07D403/04 ,  C07D401/14

CPC classification number: C07D207/273 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20160159808A1

公开(公告)日：2016-06-09

申请号：US14907139

申请日：2014-07-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masanori Kawasaki ,  Satoshi Mikami ,  Shinji Nakamura ,  Nobuyuki Negoro ,  Shuhei Ikeda ,  Izumi Nomura ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Masaki Seto ,  Shigekazu Sasaki ,  Shogo Marui ,  Takahiko Taniguchi

IPC: C07D487/04 ,  C07D498/08 ,  C07D491/08 ,  C07D471/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D473/00 ,  C07D491/08 ,  C07D498/08

Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书所述，或其盐具有PDE2A抑制作用，并且可用作精神分裂症，阿尔茨海默氏病等的预防或治疗药物。

公开(公告)号：US10323026B2

公开(公告)日：2019-06-18

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki Sugiyama ,  Jumpei Aida ,  Hidekazu Tokuhara ,  Tomohiro Okawa ,  Yuya Oguro ,  Minoru Nakamura ,  Masataka Murakami

IPC: C07D413/14 ,  C07D401/08 ,  C07D405/14 ,  C07D413/08 ,  C07D401/06 ,  C07D413/06

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US09963443B2

公开(公告)日：2018-05-08

申请号：US15316937

申请日：2015-06-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Shuhei Ikeda

IPC: A61K31/506 ,  C07D401/14 ,  A61K51/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  A61K51/0455 ,  A61K51/0459 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.

公开(公告)号：US11987586B1

公开(公告)日：2024-05-21

申请号：US18497602

申请日：2023-10-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasushi Hattori ,  Marilena Pira ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Eiji Kimura ,  Norihito Tokunaga ,  Shuhei Ikeda ,  Martin Alexander Pawliczek ,  Noriyuki Tezuka ,  Yasutaka Hoashi ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike

IPC: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.